CY1110887T1 - Χημικη in situ διαδικασια σουλφουρωσης - Google Patents

Χημικη in situ διαδικασια σουλφουρωσης

Info

Publication number
CY1110887T1
CY1110887T1 CY20101101019T CY101101019T CY1110887T1 CY 1110887 T1 CY1110887 T1 CY 1110887T1 CY 20101101019 T CY20101101019 T CY 20101101019T CY 101101019 T CY101101019 T CY 101101019T CY 1110887 T1 CY1110887 T1 CY 1110887T1
Authority
CY
Cyprus
Prior art keywords
chemical
sulfuring
situ
procedure
manufacture
Prior art date
Application number
CY20101101019T
Other languages
English (en)
Inventor
Jörgen BLIXT
Michael David Golden
Philip John Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittman
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110887(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1110887T1 publication Critical patent/CY1110887T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε χημικές διαδικασίες για τη βιομηχανική παραγωγή ορισμένων ενδιάμεσων ενώσεων χρήσιμων στη βιομηχανική παραγωγή ορισμένων παραγώγων κιναζολίνης. Συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται σε χημικές διαδικασίες για τη βιομηχανική παραγωγή ορισμένων ενδιάμεσων ενώσεων χρήσιμων στη βιομηχανική παραγωγή της ένωσης 4-(4-βρωμο-2-φθοροανιλινο)-6-μεθοξυ-7-( 1 -μεθυλπιπεριδιν-4-υλμεθοξυ)κιναζολίνη.
CY20101101019T 2005-09-30 2010-11-12 Χημικη in situ διαδικασια σουλφουρωσης CY1110887T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
EP09152654A EP2053048B8 (en) 2005-09-30 2006-09-27 Chemical in situ sulphonating process

Publications (1)

Publication Number Publication Date
CY1110887T1 true CY1110887T1 (el) 2015-06-10

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100076T CY1110275T1 (el) 2005-09-30 2010-01-25 Χημικη διαδικασια
CY20101101019T CY1110887T1 (el) 2005-09-30 2010-11-12 Χημικη in situ διαδικασια σουλφουρωσης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100076T CY1110275T1 (el) 2005-09-30 2010-01-25 Χημικη διαδικασια

Country Status (32)

Country Link
US (8) US8163926B2 (el)
EP (2) EP1943240B1 (el)
JP (2) JP5213715B2 (el)
KR (1) KR101307641B1 (el)
CN (3) CN102503898B (el)
AR (1) AR055671A1 (el)
AT (2) ATE448218T1 (el)
AU (1) AU2006296367B2 (el)
BR (1) BRPI0616715A2 (el)
CA (2) CA2624045C (el)
CY (2) CY1110275T1 (el)
DE (2) DE602006010428D1 (el)
DK (2) DK1943240T3 (el)
ES (2) ES2335435T3 (el)
GB (1) GB0519879D0 (el)
HK (2) HK1122553A1 (el)
HR (2) HRP20100019T1 (el)
IL (2) IL190172A (el)
ME (2) ME01466B (el)
MY (2) MY149834A (el)
NO (1) NO342152B1 (el)
NZ (2) NZ593930A (el)
PL (2) PL2053048T3 (el)
PT (2) PT2053048E (el)
RS (2) RS51515B (el)
RU (1) RU2448102C2 (el)
SG (1) SG165416A1 (el)
SI (2) SI2053048T1 (el)
TW (2) TWI328580B (el)
UY (1) UY29824A1 (el)
WO (1) WO2007036713A2 (el)
ZA (1) ZA200802416B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
AU2013304102B2 (en) * 2012-08-15 2016-09-01 Glaxo Group Limited Chemical process
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
ATE231505T1 (de) 1991-03-28 2003-02-15 Eisai Co Ltd Neue heterocyclische/cyclische amine
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
ATE171446T1 (de) * 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69504300T2 (de) * 1994-01-13 1999-04-29 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Gem-bissubstituierte azazyclische tachykinin-antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
ATE468339T1 (de) 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AU2003207291A1 (en) 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
CA2495487A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
CA2531862C (en) 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
HK1130478A1 (en) 2009-12-31
SI2053048T1 (sl) 2010-12-31
US20120095229A1 (en) 2012-04-19
JP5654546B2 (ja) 2015-01-14
ES2350513T3 (es) 2011-01-24
NO342152B1 (no) 2018-04-03
JP5213715B2 (ja) 2013-06-19
IL227574A (en) 2015-08-31
RS51515B (en) 2011-06-30
GB0519879D0 (en) 2005-11-09
UY29824A1 (es) 2007-04-30
ME01466B (me) 2014-04-20
EP2053048B1 (en) 2010-09-15
US9815816B2 (en) 2017-11-14
US20240150317A1 (en) 2024-05-09
DK2053048T3 (da) 2010-11-29
CN101277948A (zh) 2008-10-01
IL190172A0 (en) 2008-08-07
SI1943240T1 (sl) 2010-02-26
EP1943240B1 (en) 2009-11-11
US20180118716A1 (en) 2018-05-03
IL190172A (en) 2014-05-28
US8865899B2 (en) 2014-10-21
KR101307641B1 (ko) 2013-09-12
EP2053048B8 (en) 2011-09-21
RU2448102C2 (ru) 2012-04-20
ZA200802416B (en) 2009-01-28
HK1122553A1 (en) 2009-05-22
CA2745829C (en) 2013-07-02
CA2745829A1 (en) 2007-04-05
CA2624045A1 (en) 2007-04-05
ME01531B (me) 2014-04-20
CA2624045C (en) 2012-05-22
PL1943240T3 (pl) 2010-04-30
BRPI0616715A2 (pt) 2011-06-28
RS51263B (sr) 2010-12-31
AU2006296367B2 (en) 2011-08-11
CN102503898B (zh) 2015-03-25
HRP20100620T1 (hr) 2010-12-31
DE602006017004D1 (de) 2010-10-28
DK1943240T3 (da) 2010-03-01
NZ593930A (en) 2013-02-22
ATE481399T1 (de) 2010-10-15
TWI424991B (zh) 2014-02-01
US20090203905A1 (en) 2009-08-13
WO2007036713A3 (en) 2007-06-14
US20160185754A1 (en) 2016-06-30
CN101277948B (zh) 2013-03-13
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
ES2335435T3 (es) 2010-03-26
CN102503933A (zh) 2012-06-20
WO2007036713A2 (en) 2007-04-05
CN102503898A (zh) 2012-06-20
EP1943240A2 (en) 2008-07-16
US8163926B2 (en) 2012-04-24
DE602006010428D1 (de) 2009-12-24
EP2053048A1 (en) 2009-04-29
US20190263782A1 (en) 2019-08-29
NZ566566A (en) 2011-08-26
JP2013063998A (ja) 2013-04-11
CY1110275T1 (el) 2015-01-14
NO20081267L (no) 2008-04-30
US20140378684A1 (en) 2014-12-25
PT2053048E (pt) 2010-11-10
TWI328580B (en) 2010-08-11
PL2053048T3 (pl) 2011-03-31
AR055671A1 (es) 2007-08-29
US20220033377A1 (en) 2022-02-03
MY145540A (en) 2012-02-29
US10344015B2 (en) 2019-07-09
TW200745036A (en) 2007-12-16
HRP20100019T1 (hr) 2010-02-28
JP2009510039A (ja) 2009-03-12
AU2006296367A1 (en) 2007-04-05
TW201018660A (en) 2010-05-16
PT1943240E (pt) 2010-01-11
ATE448218T1 (de) 2009-11-15
CN102503933B (zh) 2014-06-25
MY149834A (en) 2013-10-31
RU2008116573A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
CY1110887T1 (el) Χημικη in situ διαδικασια σουλφουρωσης
CY1110520T1 (el) Παραγωγα 5-υποκατεστημενης κινολινης και ισοκινολινης· μεθοδος για την παραγωγη τους και η χρηση τους ως αντιφλεγμονωδη
TW200833667A (en) Chemical process
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
NO20081636L (no) FAP - inhibitorer
EA200701122A1 (ru) Потенциаторы рецепторов глутамата
DK2032521T3 (da) Ny fremgangsmåde til saltfremstilling
NO20082266L (no) Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser
EA200801199A1 (ru) Ингибиторы киназы
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
ATE483000T1 (de) Naphtalin-amidin-imide
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
CY1116840T1 (el) Χρηση 24-norudca
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
ATE551330T1 (de) Heterocyclische cetp-hemmer
EA200801211A1 (ru) Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах
CY1107193T1 (el) Παραγωγα πιπεραζινης και η χρηση τους ως αναστολεων της επανασυλληψης της σεροτονινης ή ως ανταγωνιστων της νευροκινινης
NO20074572L (no) Parallell identifikasjon av antibakterielle mal og inhibitorer
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer
ATE546451T1 (de) Cyclopropancarbonsäureester von acyclovir
CY1113135T1 (el) Ασυμmετρη διεργασια για την κατασκευη υποκατεστημενων 2-αμινο-θειαζολονων
EA200901063A1 (ru) Способ получения соединений мочевины (варианты) и промежуточные соединения, полученные в вышеуказанных способах (варианты)
CY1117120T1 (el) Παραγωγα 1-ν-αζακυκλοαλκυλο-3-φαινοξυπροπανιου χρησιμα για την παρασκευη ψυχοτροπων φαρμακων
TH106828A (th) สารยับยั้งไพร์โรโลไพราซีนคิเนส